Why the study?
Do serum biomarkers (cardiac troponins and natriuretic peptides) predict cardiac toxicity in breast cancer patients receiving chemotherapy and radiation therapy?
Population
Breast cancer patients receiving chemotherapy (especially anthracycline-based) and radiation therapy
Comparison
Serum biomarkers vs Routine echocardiography (current paradigm)
Design
Review
Authors
Loading...
May support troponin monitoring in anthracycline recipients; leaves open prospective validation in breast cancer on combined regimens.
Do serum biomarkers (cardiac troponins and natriuretic peptides) predict cardiac toxicity in breast cancer patients receiving chemotherapy and radiation therapy?
Serum biomarkers, particularly cardiac troponins and natriuretic peptides, represent a promising adjunct or alternative to routine echocardiography for early detection of cancer therapy-induced cardiotoxicity.
Tian et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: